Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079 · see citing works

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · see citing works

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · see citing works

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · see citing works

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · see citing works

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941 · see citing works

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108 · see citing works

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927 · see citing works

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604 · see citing works

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · see citing works

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761 · see citing works

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560 · see citing works

Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

Yusuf, S., & Jha, P. (2000) · Cited by 898 · see citing works

Herbal Medicinals: Selected Clinical Considerations Focusing on Known or Potential Drug-Herb Interactions

Miller, L. G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.20.2200 · Cited by 809 · see citing works

Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity

Juurlink, D. N., Mamdani, M., Kopp, A., Laupacis, A., & Redelmeier, D. A. (2003) · JAMA · doi:10.1001/jama.289.13.1652 · Cited by 759 · see citing works

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 508 · see citing works

Renal Dysfunction Complicating the Treatment of Hypertension

Palmer, B. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020676 · Cited by 328 · see citing works

Hyperkalemia in Hospitalized Patients

Acker, C. G., Johnson, J. P., Palevsky, P. M., & Greenberg, A. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.8.917 · Cited by 325 · see citing works

Hyperkalemia and hyporeninemic hypoaldosteronism

DeFronzo, R. A. (1980) · Kidney International · doi:10.1038/ki.1980.14 · Cited by 323 · see citing works

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

Schepkens, H., Vanholder, R. C., Billiouw, J.-M., & Lameire, N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00642-8 · Cited by 255 · see citing works

Drug-induced hyperkalemia: old culprits and new offenders

Perazella, M. A. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00496-4 · Cited by 250 · see citing works

Hyperkalemia in Outpatients Using Angiotensin-Converting Enzyme Inhibitors: How Much Should We Worry?

Reardon, L. C., & Macpherson, D. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.26 · Cited by 222 · see citing works

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

Bozkurt, B., Agoston, I., & Knowlton, A. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02694-3 · Cited by 221 · see citing works

Management of Glomerular Proteinuria: A Commentary

Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217 · see citing works

Upper Gastrointestinal Tract Injury in Patients Receiving Kayexalate (Sodium Polystyrene Sulfonate) in Sorbitol

Abraham, S. C., Bhagavan, B. S., Lee, L. A., Rashid, A., & Wu, T. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200105000-00011 · Cited by 216 · see citing works

Heparin-induced aldosterone suppression and hyperkalemia

Oster, J. R., Singer, I. I., & Fishman, L. M. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80017-5 · Cited by 205 · see citing works

Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency

Shlipak, M. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00013 · Cited by 166 · see citing works

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

Cohn, J. N., & Tognoni, G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00651-7 · Cited by 149 · see citing works

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

Pfeffer, M. A., McMurray, J. J. V., & Velazquez, E. J. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.039 · Cited by 146 · see citing works

Aldosterone in Chronic Kidney and Cardiac Disease

Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137 · see citing works

Hyperkalemia as a Complication of Drug Therapy

Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370050063011 · Cited by 128 · see citing works

Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors

Ahuja, T. S., Freeman Jr., D., Mahnken, J. D., Agraharkar, M., Siddiqui, M., & Memon, A. (2000) · American Journal of Nephrology · doi:10.1159/000013599 · Cited by 114 · see citing works

Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.

Kamel, K. S., Ethier, J. H., Quaggin, S. E., Levin, A. S., Albert, S., Carlisle, E., & Halperin, M. L. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v281279 · Cited by 110 · see citing works

A Mechanism for Pentamidine-Induced Hyperkalemia: Inhibition of Distal Nephron Sodium Transport

Kleyman, T. R., Roberts, C., & Ling, B. N. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00004 · Cited by 93 · see citing works

Clinical and demographic predictors of exercise capacity in end-stage renal disease

Sietsema, K. E., Hiatt, W. R., Esler, A. L., Adler, S. G., Amato, A., & Brass, E. P. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29884 · Cited by 92 · see citing works

Noni juice (Morinda citrifolia ): Hidden potential for hyperkalemia?

Mueller, B. A., Scott, M. K., Sowinski, K. M., & Prag, K. A. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70342-8 · Cited by 91 · see citing works

Renal complications associated with use of nonsteroidal anti-inflammatory agents.

Palmer, B. F. (1995) · PubMed · Cited by 89 · see citing works

Angiotensin converting enzyme inhibition in chronic allograft nephropathy

Lin, J., Valeri, A. M., Markowitz, G. S., Agati, V. D. R., Cohen, D. J., & Radhakrishnan, J. (2002) · Transplantation · doi:10.1097/00007890-200203150-00022 · Cited by 74 · see citing works

Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone

Cruz, C. S. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg295 · Cited by 71 · see citing works

Attenuation of Angiotensin II- and III-induced Aldosterone Release by Prostaglandin Synthesis Inhibitors

Campbell, W. B., Gómez-Sánchez, C. E., Adams, B. V., Schmitz, J. M., & Itskovitz, H. D. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109615 · Cited by 60 · see citing works

Production of Renin, Angiotensin II, and Aldosterone by Adrenal Explant Cultures: Response to Potassium and Converting Enzyme Inhibition*

Shier, D. N., KUSANO, E., Stoner, G. D., Franco-Saenz, R., & Mulrow, P. J. (1989) · Endocrinology · doi:10.1210/endo-125-1-486 · Cited by 57 · see citing works

Acute Abdomen With Colonic Necrosis Induced by Kayexalate-Sorbitol

Dardik, A., Moesinger, R. C., Efron, G., Barbul, A., & HARRISON, M. G. (2000) · Southern Medical Journal · doi:10.1097/00007611-200005000-00016 · Cited by 57 · see citing works

Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone

Young, D. B., Smith, M. J., Jackson, T. E., & Scott, R. E. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.247.3.e328 · Cited by 55 · see citing works

Hyperkalemia and Renal Insufficiency: Role of Selective Aldosterone Deficiency and Tubular Unresponsiveness to Aldosterone

Arruda, J. A. L., BATLLE, D. C., Sehy, T., Roseman, M. K., Baronowski, R. L., & Kurtzman, N. A. (2008) · American Journal of Nephrology · doi:10.1159/000166533 · Cited by 53 · see citing works

Incidence of hyperkalaemia induced by indomethacin in a hospital population.

Zimran, A., Kramer, M. R., Plaskin, M., & Hershko, C. (1985) · BMJ · doi:10.1136/bmj.291.6488.107 · Cited by 49 · see citing works

Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction

Ray, K. K., Dorman, S., & Watson, R. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000890 · Cited by 48 · see citing works

Evidence that Angiotensin-II and Potassium Collaborate to Increase Cytosolic Calcium and Stimulate the Secretion of Aldosterone*

Pratt, J. H., Rothrock, J. K., & Dominguez, J. H. (1989) · Endocrinology · doi:10.1210/endo-125-5-2463 · Cited by 39 · see citing works

Labetalol-Induced Hyperkalemia in Renal Transplant Recipients

McCauley, J., Murray, J., Jordan, M. L., Scantlebury, V. P., Vivas, C., & Shapiro, R. (2002) · American Journal of Nephrology · doi:10.1159/000065225 · Cited by 39 · see citing works

FREQUENCY OF HYPERKALEMIA IN RECIPIENTS OF SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTS WITH BLADDER DRAINAGE

Kaplan, B. E., Wang, Z., Abecassis, M. M., Fryer, J. P., Stuart, F. P., & Kaufman, D. B. (1996) · Transplantation · doi:10.1097/00007890-199610270-00025 · Cited by 36 · see citing works

Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet

Hay, E., Derazon, H., Natalia, B., Katz, L., Kruglyakov, I., & Armoni, M. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(02)00434-1 · Cited by 33 · see citing works

Herbal Interactions With Cardiac Drugs

Cheng, T. O. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.870 · Cited by 32 · see citing works

A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium

Keilani, T., Danesh, F. R., Schlueter, W. A., Molteni, A., & BATLLE, D. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70181-2 · Cited by 28 · see citing works

TRIMETHOPRIM IS A POTASSIUM-SPARING DIURETIC LIKE AMILORIDE AND CAUSES HYPERKALEMIA IN HIGH-RISK PATIENTS

Perazella, M. A. (1997) · American Journal of Therapeutics · doi:10.1097/00045391-199709000-00010 · Cited by 27 · see citing works

Effect of aging on renal function and disease

Mohamed, M. M. A. A. (2002) · Cited by 24 · see citing works

Adrenergic modulation of potassium metabolism during exercise in normal and diabetic humans

Castellino, P., Simonson, D. C., & DeFronzo, R. A. (1987) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1987.252.1.e68 · Cited by 23 · see citing works

Spironolactone and congestive heart-failure

Georges, B., Beguin, C., & Jadoul, M. Y. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72606-4 · Cited by 20 · see citing works

Hyperkalemia as a complication of drug therapy

Rimmer, J. M. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.5.867 · Cited by 12 · see citing works

Drug-induced hyperkalemia

Pantanowitz, L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00688-x · Cited by 11 · see citing works

High cytosolic pH inhibits Ca uptake by Myxicola axon mitochondria

Abercrombie, R. F., & Gammeltoft, K. (1987) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1987.252.1.c68 · Cited by 10 · see citing works

KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease

de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399 · see citing works

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · see citing works

Business Information

Rodbard, H. W., Blonde, L., Ss, B., Brett, E. M., Cobin, R. H., Handelsman, Y., Hellman, R., Jellinger, P. S., Jovanovic, L. G., Levy, P., et al. (2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 693 · see citing works

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 673 · see citing works

The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease

Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 648 · see citing works

Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639 · see citing works

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498 · see citing works

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA · doi:10.1001/jama.2015.7446 · Cited by 441 · see citing works

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes

Collins, A. J., Pitt, B., Reaven, N. L., Funk, S. E., McGaughey, K. J., Wilson, D. J., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 411 · see citing works

Diabetes mellitus and electrolyte disorders

Liamis, G. L. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i10.488 · Cited by 406 · see citing works

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

Kovesdy, C. P., Matsushita, K., Sang, Y., Brunskill, N. J., Carrero, J. J., Chodick, G., Hasegawa, T., Heerspink, H. J. L., Hirayama, A., Landman, G. W. D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy100 · Cited by 350 · see citing works

Physiology and pathophysiology of potassium homeostasis

Palmer, B. F., & Clegg, D. J. (2016) · AJP Advances in Physiology Education · doi:10.1152/advan.00121.2016 · Cited by 286 · see citing works

Cirrhosis and its complications: Evidence based treatment

Nusrat, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5442 · Cited by 284 · see citing works

Potentially Harmful Drug–Drug Interactions in the Elderly: A Review

Hines, L. E., & Murphy, J. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.10.004 · Cited by 275 · see citing works

2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension

Lee, H., Shin, J., Kim, G., Park, S., Ihm, S., Kim, H. C., Kim, K., Kim, J. H., Lee, J. H., Park, J., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0124-x · Cited by 271 · see citing works

Management of severe hyperkalemia

Weisberg, L. S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818f222b · Cited by 268 · see citing works

Use of Aldosterone Antagonists in Heart Failure

Albert, N. M. (2009) · JAMA · doi:10.1001/jama.2009.1493 · Cited by 262 · see citing works

Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy

Rossignol, P., Dobre, D., McMurray, J. J. V., Swedberg, K. B., Krum, H., van Veldhuisen, D. J., Shi, H. H., Messig, M., Vincent, J., Girerd, N., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000792 · Cited by 261 · see citing works

Electrolyte and Acid–Base Disturbances in Patients with Diabetes Mellitus

Palmer, B. F., & Clegg, D. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1503102 · Cited by 258 · see citing works

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G. S., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac401 · Cited by 238 · see citing works

Drug dosing adjustments in patients with chronic kidney disease.

Munar, M. Y., & Singh, H. (2007) · PubMed · Cited by 231 · see citing works

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

Desai, A. S., Vardeny, O., Claggett, B. L., McMurray, J. J. V., Packer, M., Swedberg, K. B., Rouleau, J. L., Zile, M. R., Lefkowitz, M. P., Shi, V. C., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4733 · Cited by 226 · see citing works

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes

Bi, Y., Li, M., Liu, Y., Li, T., Lu, J., Duan, P., Xu, F., Dong, Q., Wang, A., Wang, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2412006 · Cited by 224 · see citing works

Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence

Hiremath, S. S., Fergusson, D. A., Doucette, S. P., Mulay, A. V., & Knoll, G. A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01928.x · Cited by 209 · see citing works

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Rosano, G. M. C., Tamargo, J. L., Kjeldsen, K. P., Lainščak, M., Agewall, S., Anker, S. D., Ceconi, C., Coats, A. J. S., Drexel, H., Filippatos, G. S., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy015 · Cited by 204 · see citing works

Effects of dapagliflozin in stage 4 chronic kidney disease

Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201 · see citing works

Management of hyperkalaemia in chronic kidney disease

Kovesdy, C. P. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.168 · Cited by 200 · see citing works

Associations of serum potassium levels with mortality in chronic heart failure patients

Aldahl, M., Jensen, A.-S. C., Davidsen, L., Eriksen, M. A., Hansen, S. M., Nielsen, B. J., Krogager, M. L., Køber, L., Torp-Pedersen, C. T., & Søgaard, P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx460 · Cited by 197 · see citing works

Abnormalities of Potassium in Heart Failure

Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 197 · see citing works

Clinical Management of Hyperkalemia

Palmer, B. F., Carrero, J. J., Clegg, D. J., Colbert, G. B., Emmett, M., Fishbane, S. N., Hain, D. J., Lerma, E. V., Onuigbo, M. A. C., Rastogi, A., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.014 · Cited by 195 · see citing works

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 187 · see citing works

Prevalence and Factors Associated with Hyperkalemia in Predialysis Patients Followed in a Low-Clearance Clinic

Sarafidis, P. A., Blacklock, R. M., Wood, E., Rumjon, A., Simmonds, S., Fletcher-Rogers, J., Ariyanayagam, R., Al-Yassin, A., Sharpe, C. C., & Vinen, K. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01150112 · Cited by 184 · see citing works

Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension

Saha, C., Eckert, G., Ambrosius, W., Chun, T., Wagner, M. A., Zhao, Q.-Q., & Pratt, J. (2005) · HYPERTENSION · doi:10.1161/01.hyp.0000179582.42830.1d · Cited by 180 · see citing works

Renal Failure Associated with Cancer and Its Treatment

Humphreys, B. D., Soiffer, R. J., & Magee, C. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100843 · Cited by 177 · see citing works

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.067 · Cited by 170 · see citing works

Validity of the International Classification of Diseases, Tenth Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission

Hwang, Y. J., Shariff, S. Z., Gandhi, S., Wald, R., Clark, E. G., Fleet, J. L., & Garg, A. X. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001821 · Cited by 167 · see citing works

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials

Ezekowitz, J. A., & McAlister, F. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn543 · Cited by 166 · see citing works

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164 · see citing works

Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease

Nakhoul, G., Huang, H., Arrigain, S., Jolly, S. E., Schold, J. D., Nally, J. V., & Navaneethan, S. D. (2015) · American Journal of Nephrology · doi:10.1159/000437151 · Cited by 161 · see citing works

Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review

Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 160 · see citing works

Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors

Pitt, B., Bakris, G. L., Bushinsky, D. A., Garza, D., Mayo, M. R., Stasiv, Y., Christ‐Schmidt, H., Berman, L., & Weir, M. R. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.402 · Cited by 159 · see citing works

Drug-Induced Hyperkalemia

Salem, C. B., Badreddine, A., Fathallah, N., Slim, R., & Hmouda, H. (2014) · Drug Safety · doi:10.1007/s40264-014-0196-1 · Cited by 149 · see citing works

Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145 · see citing works

Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes

Khanagavi, J., Gupta, T., Aronow, W. S., Shah, T. M., Garg, J., Ahn, C. W., Sule, S. S., & Peterson, S. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.42577 · Cited by 144 · see citing works

Treatment of hyperkalemia: something old, something new

Sterns, R. H., Grieff, M., & Bernstein, P. L. (2016) · Kidney International · doi:10.1016/j.kint.2015.11.018 · Cited by 141 · see citing works

Management of Hyperkalemia: An Update for the Internist

Kovesdy, C. P. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.040 · Cited by 140 · see citing works

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System

Antoniou, T. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.142 · Cited by 137 · see citing works

Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lakhdar, R., Al-Mallah, M. H., & Lanfear, D. E. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.11.008 · Cited by 128 · see citing works

A recent review of citrus flavanone naringenin on metabolic diseases and its potential sources for high yield-production

Karim, N., Jia, Z., Zheng, X., Cui, S., & Chen, W. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.06.012 · Cited by 128 · see citing works

Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)

Fried, L. F., Duckworth, W. C., Zhang, J. H., O’Connor, T., Brophy, M. T., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S. L., et al. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03350708 · Cited by 127 · see citing works

Diagnosis and treatment of hyperkalemia

Palmer, B. F., & Clegg, D. J. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.17056 · Cited by 127 · see citing works

Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future

Rossignol, P., Legrand, M. M., Kosiborod, M., Hollenberg, S. M., Peacock, W. F., Emmett, M., Epstein, M., Kovesdy, C. P., Yılmaz, M. B., Stough, W. G., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.039 · Cited by 126 · see citing works

Hyperkalemia in Heart Failure

Sarwar, C. M. S., Papadimitriou, L., Pitt, B., Piña, I. L., Zannad, F. M., Anker, S. D., Gheorghiade, M., & Butler, J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.060 · Cited by 116 · see citing works

Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia

Meaney, C. J., Beccari, M. V., Yang, Y., & Zhao, J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1906 · Cited by 115 · see citing works

Renal Tubular Acidosis and Management Strategies: A Narrative Review

Palmer, B. F., Kelepouris, E., & Clegg, D. J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01587-5 · Cited by 115 · see citing works

Updates in hyperkalemia: Outcomes and therapeutic strategies

Kovesdy, C. P. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9384-x · Cited by 111 · see citing works

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Bushinsky, D. A., Williams, G. H., Pitt, B., Weir, M. R., Freeman, M. W., Garza, D., Stasiv, Y., Li, E., Berman, L., & Bakris, G. L. (2015) · Kidney International · doi:10.1038/ki.2015.270 · Cited by 110 · see citing works

Chronic Kidney Disease in Diabetes

McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 105 · see citing works

Chronic Kidney Disease in Diabetes

McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.037 · Cited by 102 · see citing works

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study

Fralick, M., Macdonald, E. M., Gomes, T., Antoniou, T., Hollands, S., Mamdani, M. M., & Juurlink, D. N. (2014) · BMJ · doi:10.1136/bmj.g6196 · Cited by 102 · see citing works

Poly(methyl methacrylate)s with Pendant Calixpyrroles and Crown Ethers: Polymeric Extractants for Potassium Halides

Aydogan, A., Coady, D. J., Kim, S. K., Akar, A., Bielawski, C. W., Márquez, M., & Sessler, J. L. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200803970 · Cited by 102 · see citing works

Potassium Metabolism and Management in Patients with CKD

Yamada, S., & Inaba, M. (2021) · Nutrients · doi:10.3390/nu13061751 · Cited by 101 · see citing works

Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension

Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.09.011 · Cited by 99 · see citing works

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Miao, Y., Dobre, D., Heerspink, H. J. L., Brenner, B. M., Cooper, M. E., Parving, H.-H., Shahinfar, S., Grobbee, D. E., & de Zeeuw, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1922-6 · Cited by 98 · see citing works

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study

Thomsen, R. W., Nicolaisen, S. K., Hasvold, P., Sanchez, R. G., Pedersen, L. H., Adelborg, K., Egstrup, K., Egfjord, M., & Sørensen, H. T. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx312 · Cited by 96 · see citing works

Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension

Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.09.003 · Cited by 95 · see citing works

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan

Kashihara, N., Kohsaka, S., Kanda, E., Okami, S., & Yajima, T. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.05.018 · Cited by 94 · see citing works

A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients

Antonio Vukusich, C., Sonia Kunstmann, F., Varela, C., Daniela Gainza, K., Bravo, S., Sepúlveda, D., Cavada, G., Michea, L., & Marusic, E. T. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09421209 · Cited by 94 · see citing works

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

Ferreira, J. P., Zannad, F. M., Butler, J., Filipattos, G., Ritter, I., Schueler, E., Kraus, B. J., Pocock, S., Anker, S. D., & Packer, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac306 · Cited by 92 · see citing works

Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management

de Sousa, A. G. P., Cabral, J. V., El-Feghaly, W. B., sousa, L. K. L., & Nunes, A. B. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i5.101 · Cited by 92 · see citing works

Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers

Raebel, M. A., McClure, D. L., Simon, S. R., Chan, K. A., Feldstein, A. C., Andrade, S. E., Lafata, J. E., Roblin, D. W., Davis, R. L., Gunter, M. J., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1217 · Cited by 87 · see citing works

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis

Vukadinović, D., Lavall, D., Vukadinović, A. N., Pitt, B., Wagenpfeil, S., & Böhm, M. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.011 · Cited by 87 · see citing works

Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021

Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 86 · see citing works

A Physiologic-Based Approach to the Evaluation of a Patient With Hypokalemia

Palmer, B. F. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.07.010 · Cited by 86 · see citing works

Pathophysiology, therapy, and oral implications of renal failure in children and adolescents: an update.

Davidovich, E., Davidovits, M., Eidelman, E., Schwarz, Z., & Bimstein, E. (2005) · PubMed · Cited by 85 · see citing works

A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes

Singer, A. J., Thode, H. C., & Peacock, W. F. (2017) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.16.194 · Cited by 83 · see citing works

Metabolic Complications Associated With Use of Diuretics

Palmer, B. F. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.09.009 · Cited by 83 · see citing works

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

Bamberg, K., Johansson, U., Edman, K., William‐Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Granqvist, A., Jaisser, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193380 · Cited by 82 · see citing works

Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease

Palmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000101958 · Cited by 82 · see citing works

Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes

Thomsen, R. W., Nicolaisen, S. K., Hasvold, P., García‐Sánchez, R., Pedersen, L. H., Adelborg, K., Egfjord, M., Egstrup, K., & Sørensen, H. T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008912 · Cited by 81 · see citing works

New Potassium Binders for the Treatment of Hyperkalemia

Pitt, B., & Bakris, G. L. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.04889 · Cited by 79 · see citing works

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies

Humphrey, T. J. L., Davids, M. R., Chothia, M., Pecoits‐Filho, R., Pollock, C. A., & James, G. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab243 · Cited by 77 · see citing works

Potassium and Its Discontents

Ellison, D. H., Terker, A. S., & Gamba, G. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070751 · Cited by 76 · see citing works

Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring

Raebel, M. A., Ross, C. A., Xu, S., Roblin, D. W., Cheetham, C., Blanchette, C. M., Saylor, G., & Smith, D. H. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1228-x · Cited by 74 · see citing works

Targeting Outpatient Drug Safety

Herwaarden, M. F. W., Kramers, C., Sturkenboom, M., van den Bemt, P. M. L. A., & Smet, P. A. G. M. D. (2012) · Drug Safety · doi:10.2165/11596000-000000000-00000 · Cited by 74 · see citing works

Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena

Epstein, M. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.004 · Cited by 74 · see citing works

Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission

Fleet, J. L., Shariff, S. Z., Gandhi, S., Weir, M. A., Jain, A. K., & Garg, A. X. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-002011 · Cited by 69 · see citing works

Analysis of Factors Causing Hyperkalemia

Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 69 · see citing works

Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management

Hundemer, G. L., & Sood, M. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105835 · Cited by 67 · see citing works

Effects of Presentation and Electrocardiogram on Time to Treatment of Hyperkalemia

Freeman, K., Feldman, J. A., Mitchell, P. M., Donovan, J., Dyer, K. S., Eliseo, L. J., White, L. F., & Temin, E. S. (2008) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2008.00058.x · Cited by 67 · see citing works

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia

Barrera‐Chimal, J., Prince, S., Fadel, F., Moghrabi, S. E., Warnock, D. G., Kolkhof, P., & Jaisser, F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121216 · Cited by 65 · see citing works

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review

Beccari, M. V., & Meaney, C. J. (2017) · Core evidence · doi:10.2147/ce.s129555 · Cited by 65 · see citing works

Serum Potassium in the PARADIGM-HF Trial

Ferreira, J. P., Mogensen, U. M., Jhund, P. S., Desai, A. S., Rouleau, J. L., Zile, M. R., Rossignol, P., Zannad, F. M., Packer, M., Solomon, S. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1987 · Cited by 64 · see citing works

Clinical-pharmacist intervention reduces clinically relevant drug–drug interactions in patients with heart failure: A randomized, double-blind, controlled trial

Roblek, T., Detiček, A., Leskovar, B., Šuškovič, S., Horvat, M., Belic, A., Mrhar, A., & Lainščak, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.206 · Cited by 63 · see citing works

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

Yavin, Y., Mansfield, T. A., Ptaszynska, A., Johnsson, K. M., Parikh, S. J., & JOHNSSON, E. K. (2016) · Diabetes Therapy · doi:10.1007/s13300-015-0150-y · Cited by 62 · see citing works

Blood pressure drug therapy and electrolyte disturbances

Liamis, G. L., Milionis, H. J., & Elisaf, M. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01860.x · Cited by 61 · see citing works

CKD as an Underrecognized Threat to Patient Safety

Fink, J. C., Brown, J., Hsu, V. D., Seliger, S. L., Walker, L. D., & Zhan, M. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.016 · Cited by 60 · see citing works

Hyperkalemia in patients with heart failure: Incidence, prevalence, and management

Desai, A. S. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0037-1 · Cited by 59 · see citing works

Risk of hyperkalemia and combined use of spironolactone and long‐term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real‐life data: a population‐ and insurance‐based cohort

Abbas, S., Ihle, P., Harder, S., & Schübert, I. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3748 · Cited by 59 · see citing works

Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease

Pitt, B., Bushinsky, D. A., Kitzman, D. W., Ruschitzka, F. T., Metra, M., Filippatos, G. S., Rossignol, P., Mond, C. D., Garza, D., Berman, L., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12265 · Cited by 58 · see citing works

Systematic Review Of Hyperkalemia Due To Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Topaloglu, H., & Kumar, S. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.898

Systematic Review of Burden of Hyperkalemia due to Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Kumar, S., & Topaloglu, H. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.082

Hyperkalemia and Inhibitors of the Renin–Angiotensin–Aldosterone System

Segal, A. Z. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412023512321 · Cited by 2 · see citing works

Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Closer Look at Hyperkalemia

Chung, S., & Park, C. W. (2011) · The Korean Journal of Internal Medicine

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 187 · see citing works